TransMedics Group, Inc. (NASDAQ:TMDX) Shares Sold by Baillie Gifford & Co.

Baillie Gifford & Co. lowered its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 8.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 234,889 shares of the company’s stock after selling 22,577 shares during the period. Baillie Gifford & Co. owned approximately 0.70% of TransMedics Group worth $36,878,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in TMDX. Vaughan Nelson Investment Management L.P. acquired a new position in TransMedics Group in the second quarter valued at $39,862,000. Driehaus Capital Management LLC grew its position in shares of TransMedics Group by 15.8% during the second quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock worth $223,832,000 after buying an additional 202,867 shares in the last quarter. Principal Financial Group Inc. increased its stake in shares of TransMedics Group by 260.1% in the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock worth $31,759,000 after buying an additional 146,115 shares during the last quarter. Hood River Capital Management LLC acquired a new stake in TransMedics Group in the second quarter valued at $18,854,000. Finally, Canada Pension Plan Investment Board acquired a new position in TransMedics Group during the 2nd quarter worth $16,086,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Trading Up 2.6 %

TransMedics Group stock opened at $91.41 on Wednesday. TransMedics Group, Inc. has a 52-week low of $56.83 and a 52-week high of $177.37. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The firm has a market capitalization of $3.07 billion, a price-to-earnings ratio of 97.25 and a beta of 2.08. The firm has a 50-day moving average price of $130.45 and a two-hundred day moving average price of $139.89.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. During the same quarter in the prior year, the firm posted ($0.12) earnings per share. The business’s quarterly revenue was up 63.7% on a year-over-year basis. Sell-side analysts expect that TransMedics Group, Inc. will post 1.07 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Piper Sandler reissued an “overweight” rating and issued a $180.00 price objective on shares of TransMedics Group in a report on Tuesday, October 29th. Baird R W raised shares of TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. JPMorgan Chase & Co. dropped their target price on shares of TransMedics Group from $173.00 to $116.00 and set an “overweight” rating on the stock in a report on Tuesday, October 29th. Needham & Company LLC reduced their price target on shares of TransMedics Group from $208.00 to $109.00 and set a “buy” rating on the stock in a research report on Tuesday, October 29th. Finally, Canaccord Genuity Group lowered their price objective on shares of TransMedics Group from $169.00 to $109.00 and set a “buy” rating for the company in a research report on Tuesday, October 29th. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $144.80.

Insider Transactions at TransMedics Group

In related news, Director Edward M. Basile sold 6,750 shares of TransMedics Group stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total transaction of $563,962.50. Following the sale, the director now directly owns 732 shares in the company, valued at $61,158.60. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Nicholas Corcoran sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total value of $1,760,200.00. Following the completion of the sale, the insider now directly owns 21,105 shares of the company’s stock, valued at approximately $3,714,902.10. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Edward M. Basile sold 6,750 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total transaction of $563,962.50. Following the transaction, the director now owns 732 shares in the company, valued at $61,158.60. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 36,958 shares of company stock valued at $5,230,528. 7.00% of the stock is currently owned by corporate insiders.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.